Pharm-Eco Laboratories, Inc.

Interneuron Pharmaceuticals, Inc.

Johnson Matthey Pharmaceutical Materials, Inc.

Pharma-Eco Laboratories, Inc.

Salah A Zahr

Yesh P Sachdeva

Richard L Gabriel

Emile Al-Farhan

Siya Ram

Jaechul Shim

Biman Pal

Bing Cai

Adel M Moussa

David A Swanson

Emile M Bellott

Kenneth W Locke

Kay Jorgenson D'Orlando

Subramaniam Krishnananthan

Michael D Nohrden

Luning Han

Jurjus Jurayj

Changhua Liu

Brittany La

Sharon Fitzhenry

The present invention relates to a method of preparing enantiomers and diastereomers of a 2&prime;,3&prime;-dideoxy-5-fluoro-3&prime;thiocytadine (FTC) or a derivative thereof as represented by the structural formula (I), wherein R is H, a substituted or unsubstituted organic acid radical, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted heteroarakyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstitued cycloalkylalkyl group, a substituted or unsubstituted heterocycloalkylalkyl group, a sugar or a protecting group.

Methods of separating FTC isomers and derivatives thereof

Synthesis of nitroalcohol diastereomers

Amino acid-derived diaminopropanols

The present invention relates to a method of forming a 1,3-diamino-3-substituted-2-propanol chemical intermediate from which various chemicals, such as selected protease-inhibitors and other drugs, as well as polymers, can be synthesized. This method includes contacting a nitromethyl amino acid compound with at least one reducing agent to form the 1,3-diamino-3-substituted-2-propanol chemical intermediate.

Method of forming amino acid-derived diaminopropanols useful as chemical

Method forming protease inhibitor synthetic intermediates

The present invention relates to a method of forming a 1,3-diamino-3-substituted-2-propanol chemical intermediate from which various chemicals, such as selected protease-inhibitors and other drugs, as well as polymers, can be synthesized. The method includes contacting a nitromethyl amino acid compound with at least one reducing agent to form the 1,3-diamino-3-substituted-2-propanol chemical intermediate.

This invention relates to novel substituted tryptamine and phenalkylamine and related compounds, pharmaceutical compositions thereof and methods of using said compounds.

Substituted tryptamines phenalkylamines and related compounds

Method preparing amino acid-derived diaminopropanols

This invention relates to novel substituted tryptamine and phenalkylamine and related compounds, pharmaceutical compositions thereof and methods of using said compounds and compositions for a number of pharmaceutical indications including (but not limited to): 1. central nervous system and psychiatric disorders (e.g., sleep disorders, epilepsy and other convulsive disorders, anxiety, psychiatric diseases, neurodegenerative diseases, fever); 2. chronobiological-based disorders (e.g., jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder); 3. endocrine indications (e.g., contraception and infertility, precocious puberty, premenstrual syndrome, hyperprolactinemia, growth hormone deficiency); 4. cancer and other proliferative diseases; 5. immune system disorders and conditions associated with senescence; 6. ophthalmological diseases; 7. animal breeding (e.g., regulation of fertility, puberty, pelage color).

Substituted tryptamines, phenalkylamines and related compounds

Growing community of inventors

Acton, MA, United States of America

Salah A Zahr